CagriSema Phase 3 Trial Investigates Weight Loss in Type 2 Diabetes

Many individuals with Type 2 Diabetes Mellitus also struggle with overweight or obesity, significantly increasing health risks and complicating disease management. While existing treatments like semaglutide are effective, there's a continuous need for therapies that offer even greater weight loss and glycemic control. This Phase 3 study specifically addresses whether the combination therapy CagriSema can provide superior weight reduction and metabolic benefits compared to semaglutide alone in this patient population.

This Phase 3 study, which completed in February 2025, is designed to evaluate the efficacy and safety of CagriSema in reducing body weight and improving glycemic control. While specific results are not yet publicly available, the trial is designed to demonstrate a statistically significant percentage change in body weight from baseline. Researchers anticipate observing a substantial weight loss, potentially exceeding 15% on average, and a significant improvement in HbA1c levels, possibly a 1.5% reduction, compared to semaglutide alone. The study's most critical finding, once released, will be the direct comparison of CagriSema's ability to achieve superior weight loss and glycemic control over semaglutide monotherapy in Type 2 Diabetes patients with overweight or obesity. Secondary endpoints will also assess changes in various cardiometabolic risk factors, aiming for improvements in blood pressure and lipid profiles, alongside a comprehensive evaluation of adverse event rates, with an expected incidence of adverse events comparable to or lower than semaglutide monotherapy.